albert a. chemical aspects of chemical toxicity. nature...
TRANSCRIPT
216
1. Albert A. Chemical aspects of chemical toxicity. Nature, 182,
1958; 421-423.
2. Albert A. Selective toxicity. John Wiley and Sons, New York, 1964;
57–63.
3. Harper NJ. Drug Latentiation. J. Med. Chem., 1,1959; 467-500.
4. Harper NJ. Drug Latentiation. Prog. Drug Res., 4, 1962; 221–294.
5. Kupchan SM, Casy AF, Swintosky JV. Drug latentiation-
Synthesis and preliminary evaluation of testosterone derivatives.
J. Pharm. Sci., 54, 1965; 514-524.
6. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen
T, Savolainen J. Prodrugs: design and clinical applications. Nat.
Rev., 7, 2008; 255-270.
7. Sinkula AA, Yalkowsky SH. Rationale for the design of biologically
reversible derivatives: Prodrugs. J. Pharm. Sci., 64, 1975; 181–
210.
8. Stella VJ, Charman WN, Naringrekar VH. Prodrugs: Do they have
advantages in clinical practice?, Drugs, 29, 1985; 455–473.
9. Bundgaard H. The double prodrug concept and its applications.
Adv. Drug. Deliv. Rev., 3, 1989; 39–65.
10. Ariens EJ, Simonis AM. Drug action: Target tissue, dose response
relationships and receptors. In: Pharmacology and
Pharmacokinetics (Torell T. Eds.), Plenum Press, New York, 1974;
163-189.
217
11. Higuchi T, Davis SSI. Thermodynamic analysis of structure-
activity relationships of drugs: Prediction of optimal structure. J.
Pharm. Sci., 59, 1970; 1376-1383.
12. Hansch C. The physicochemical approach to drug design and
discovery (QSAR). Drug Dev. Res., 1, 1981; 267-309.
13. Davies GE, Driver GW, Hoggarth E, Martin AR, Paige MFC, Rose
FL, Wilsor BR. Studies in the chemotherapy of tuberculosis: ethyl
mercaptan and related compounds. Br. J. Pharmacol.
Chemother., 11, 1956; 351–356.
14. Davis GE, Driver GW. The anti tuberculous activity of ethyl
thiolesters, with particular reference to diethyl
dithiolisophthalate. Br. J. Pharmacol. Chemother., 12, 1957;
434–437.
15. Novak E, Wagner JG, Lamb DL. Local and systemic tolerance,
absorption and excretion of clindamycin hydrochloride after
intramuscular administration. Int. J. Clin. Pharmacol. Ther.
Toxicol., 3, 1970; 201-208.
16. Gray JE, Weaver RN, Moron J, Feenstra ES. The parenteral
toxicity of clindamycin-2-phosphate in laboratory animals.
Toxicol. Appl. Pharmacol., 27, 1974; 308–321.
17. DeHaan RM, Mertzler CM, Schellenberg D, Vandenbosch WD.
Pharmacokinetic studies of clindamycin phosphate. J. Clin.
Pharmacol., 13, 1973; 190-209.
218
18. Varia SA, Schullar S, Stell VJ. Phenytoin prodrugs IV: Hydrolysis
of various 3-(hydroxy methyl)phenytoin esters. J. Pharm. Sci., 73,
1984; 1074–1080.
19. Glazko AJ, Edgerton WH, Dill WA, Lenz WR. Chloromycetin
palmitate - A synthetic ester of chloromycetin. Antibiot.
Chemother., 2, 1952; 234-241.
20. Shen TY, Winter CA. In: Advances in drug research (Harper NJ,
Summonds AB. Eds.), Academic Press, New York, 1977; 89-246.
21. Duggan DE, Hare LE, Ditzler CA, Lei BW, Kwan KC. The
disposition of sulindac. Clin. Pharmacol. Ther., 21, 1977; 326–
335.
22. Bundgaard H. Spectrophotometric determination of ampicillin
sodium in presence of its degradation and polymerization
products. J. Pharm. Pharmacol., 26, 1974; 385–392.
23. Stewart BH, Amidon GL, Brabec RK. Uptake of prodrugs by rat
intestinal mucosal cells: mechanism and pharmaceutical
implications. J. Pharm. Sci., 75, 1986; 940-945.
24. Schwartz MA, Hayton WL. Relative stability of hetacillin and
ampicillin in solution. J. Pharm. Sci., 1972, 61; 906–909.
25. Ho NFH, Park JY, Morozowich W, Higuchi WI. In: Design of
biopharmaceutical properties through prodrugs and analogs
(Roche EB. Eds.), American Pharmaceutical Association,
Washington DC, 1977; 136-227.
26. Glazko AJ, Dill WA, Wheelock RH, Young RM, Nemanich A,
Coskey L, Stella V, Higuchi T. In: Prodrugs as novel drug delivery
219
system (Higuchi T, Stella V. Eds.), American Chemical Society,
Washington DC, 1975; 184-195.
27. Ehrnebo M, Nilsson SO, Boreus LO. Pharmacokinetics of
ampicillin and its prodrugs bacampicillin and pivampicillin in
man. J. Pharmacokinet. Biopharm., 7, 1979; 429–451.
28. Loo JC, Foltz EL, Wallick H, Kwan KC. Pharmacokinetics of
pivampicillin and ampicillin in man. Clin. Pharmacol. Ther., 16,
1974; 35–43.
29. Clayton JP, Cole M, Elson SW, Hardy KD, Mizen LW, Sutherland
R. Preparation, hydrolysis, and oral absorption of alpha-carboxy
esters of carbenicillin. J. Med. Chem., 18, 1975; 172–177.
30. Fabre J, Burgy C, Rundhardt M, Herrera A. The behaviour in
man of C.P.15, 464, a carbenicillin absorbed following oral
administration. Chemother., 17, 1972; 334–343.
31. Megges R, Portius HJ, Repke KRH. Penta-acetyl-gitoxin: the
prototype of a prodrug in the cardiac glycoside series. Pharmazie,
32, 1977; 665–667.
32. Beyer KH, Govier WMM. The deamination of "marfanil" and
related compounds. Science, 101, 1945; 150-151.
33. Barry BW, Woodford R. Comparative bio-availability of proprietary
topical corticosteroid preparations: vasoconstrictor assays on
thirty creams and gels. Br. J. Dermatol. 91, 1974; 323-338.
34. Gibaldi M, Boyes RN, Feldman S. Influence of first-pass effect on
availability of drugs on oral administration. J. Pharm. Sci., 60,
1971; 1338–1340.
220
35. Schedl HP, Clifton JA. Small intestinal absorption of steroids.
Gastroenter., 41, 1961; 491–499.
36. Bodor N, Farag HH, Brewster ME. Site-specific, sustained release
of drugs to the brain. Science, 214, 1981; 1370-1372.
37. Ebert AG, Hess SM. The distribution and metabolism of
fluphenazine enanthate. J. Pharmacol. Exp. Ther., 148, 1965;
412-421.
38. Yale HL. Esters of 4-[3-[2-(trifluoromethyl) phenothiazin-10-yl]
propyl]-1-piperazineethanol and related compounds as long-
acting antipsychotic agents. Synthesis of the 1-adamantoate, the
first crystalline base. J. Med. Chem., 20, 1977; 302–304.
39. Alibrandi A, Brani G, Erioli A, Gardi R, Melt P. Factors
influencing the biological activity of orally administered steroid
compounds: effect of the medium and of esterification.
Endocrinol., 66, 1960; 13–18.
40. Notari RE. In: Design of biopharmaceutical properties through
prodrugs and analogs (Roche EB. Eds.), American
Pharmaceutical Association, Washington DC, 1977; 68–97.
41. Vane JR. In: Prostaglandin synthesis inhibitors: Their effects on
physiological functions and pathological states (Robinson, Vane
Eds.), Raven Press, New Delhi, 1974; 1-155.
42. Mandell AI, Stentz F, Kitabchi AE. Dipivalyl epinephrine: a new
prodrug in the treatment of glaucoma. Opthalmol., 85, 1978;
268-275.
221
43. Wise R. After pro-drugs-mutual pro-drugs. J. Antimicrob.
Chemother., 7, 1981; 503-504.
44. Kopecek J, Duncan R. Targetable Polymeric Prodrugs. J. Contr.
Rel., 6, 1987; 315–327.
45. Halen PK, Murumkar PR, Giridhar R, Yadav MR. Prodrug
designing of NSAIDs. Mini-Rev. Med. Chem., 9, 2009; 124-139.
46. Block JH, Beale JM. Organic medicinal and pharmaceutical
chemistry, Lippincott Williams and Wilkins, Philadelphia, USA,
2004; 143-148.
47. Johansen M, Bundgaard H. Solubility, dissolution and
partitioning behaviour of N-Mannich bases and N-hydroxy methyl
derivatives. Arch. Pharm. Chem. Sci. Edn., 8, 1980; 141–151.
48. Ferres H. Prodrugs of beta-lactam antibiotics. Chem. Ind., 11,
1980; 435−440.
49. Buur A, Bundgaard H. Prodrug of 5-fluorouracil V. 1-alkoxy
carbonyl derivatives as potential prodrug forms for improved
rectal or oral delivery of 5-fluorouracil. J. Pharm. Sci., 75, 1986;
522–527.
50. Bundgaard H. In: Design of prodrugs. Elsevier science publishers,
Amsterdam, 1985; 99-192.
51. Bundgaard H, Falch E, Larsen C, Mosher GL, Mikkelson TJ.
Pilocarpic acid esters as novel sequentially labile pilocarpine
prodrugs for improved ocular delivery. J. Med. Chem., 28, 1985;
979-981.
222
52. Stella VJ, Himmelstein KJ. Prodrugs and site-specific drug
delivery. J. Med. Chem., 23, 1980; 1275-1282.
53. Wilk S, Mizoguchi H, Orlowski M. Gamma-glutamyl dopa: a
kidney-specific dopamine precursor. J. Pharm. Exp. Ther., 206,
1978; 227-232.
54. Friend DR, Chang GW. A colon-specific drug-delivery system
based on drug glycosides and the glycosidase of colonic bacteria.
J. Med. Chem., 27, 1984; 261-266.
55. Yalkowsky SH, Morozowich W. In: Drug design IX (Ariens EJ
Eds.), Academic Press, London, 1980; 121-185.
56. AshuthoshKar. Medicinal chemistry, New Age International
Publishers, New Delhi, India, 2007; 522-580.
57. McAdam BF, Lawson CF, Mardini IA. Systemic biosynthesis of
prostacyclin by cyclooxygenase (COX)-2: the human
pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad.
Sci. USA, 96, 1999; 272–277.
58. Vane JR. Introduction: Mechanism of action of NSAIDs. Br. J.
Rheumat., 35(S-1), 1996; 1-3.
59. Engelhardt G, Homma D, Schlegel K, Schnitzler C, Utzmann R.
Anti-inflammatory, analgesic, antipyretic and related properties of
meloxicam, a new non-steroidal anti inflammatory agent with
favourable gastrointestinal tolerance. Inflamm. Res., 44, 1995;
423-433.
223
60. Graham DY, Agrawal NM, Campbell DR. Ulcer prevention in long-
term users of non steroidal anti inflammatory drugs. Arch. Intern.
Med., 162, 2002; 169-175.
61. Gold BD, Scheiman JM, Sabesin SM, Vitat P. Updates on the
management of upper gastrointestinal disorders in the primary
care setting: NSAID related gastropathies and pediatric reflux
disease. Suppl. J. Fam. Prac., 56, 2007; 1-12.
62. Paris GY, Garmaise DL, Cimon DG, Swett L, Carter GW, Young P.
Glycerides as prodrugs. 3. Synthesis and antiinflammatory
activity of [1-(p-chlorobenzoyl)-5-methoxy-2-methyl indole-3-
acetyl] glycerides (indomethacin glycerides). J. Med. Chem., 23,
1980; 9-13.
63. Allen RC. In: Annual Reports in Medicinal Chemistry (Bailey DM
Ed.), Academic Press, Orlando, 19, 1984; 313-326.
64. Allen RC. In: Annual Reports in Medicinal Chemistry (Bailey DM.
Ed.), Academic Press, Orlando, 20, 1985; 315- 325.
65. Allen RC. In: Annual Reports in Medicinal Chemistry (Bailey DM.
Ed.), Academic Press, Orlando, 21, 1986; 323-335.
66. Allen RC. In: Annual Reports in Medicinal Chemistry (Bailey DM.
Ed.), Academic Press, Orlando, 22, 1987; 315-330.
67. Cherie LG, Montagnani G, Alberici M, Acerbi D. Plasma and
synovial fluid concentrations of piroxicam during prolonged
treatment with piroxicam pivalic ester. Arzneimittelforschung, 37,
1987; 560–563.
224
68. Ong HH, Allen RC. In: Annual Reports in Medicinal Chemistry
(Allen RC. Ed.), Academic Press, San Diego, 23, 1988; 325-348.
69. Nielsen NM, Bundgaard H. Glycolamide esters as biolabile
prodrugs of carboxylic acid agents: Synthesis, stability,
bioconversion, and physicochemical properties. J. Pharm. Sci.,
77, 1988; 285–298.
70. Venuti MC, Young JM, Maloney PJ, Johnson D, McGreevy K.
Synthesis and biological evaluation of Ω-(N,N,N-trialkyl
ammonium)alkyl esters and thioesters of carboxylic acid non
steroidal antiinflammatory agents. Pharma. Res., 6, 1989; 867–
873.
71. Kahns AH, Jensen PB, Mork N, Bundgaard H. Kinetics of
hydrolysis of indomethacin and indomethacin ester prodrugs in
aqueous solution. Acta Pharm. Nord., 1, 1989; 327–336.
72. Kuriyama K, Hiyama Y, Aoyama Y, Ichikawa K, Okumura M,
Masumoto S, Ito K, Ohtaki Y, Hirata M, Hanada S.
Pharmacological studies of a non-steroidal analgesic and
antipyretic drug of LFP83. Nippon Yakurigaku Zasshi, 93, 1989;
61–73.
73. Nielsen NM, Bundgaard H. Evaluation of glycolamide esters and
various other esters of aspirin as true aspirin prodrugs. J. Med.
Chem., 32, 1989; 727–734.
74. Jeremy JY, Thompson CS, Mikhailidis DP, Dandona P. Effect of
the anti inflammatory prodrug, nabumetone and its principal
active metabolite on rat gastric mucosal, aortic and platelet
225
eicosanoid synthesis, in vitro and ex vivo. Prostaglandins, Leukot.
Essent. Fatty Acids, 41, 1990; 195–199.
75. Ong HH, Allen RC. In: Annual Reports in Medicicnal Chemistry
(Bristol JA. Ed.), Academic Press, San Diego, 25, 1990; 309-322.
76. Strupczewski JD, Ellis DB, Allen RC. In: Annual Reports in
Medicinal Chemistry (Bristol JA. Ed.), Academic Press, San Diego,
26, 1991; 297-313.
77. Oga S, Taniguchi SF, Najjar R, Souza AR. Synthesis,
characterization, and biological screening of a copper flurbiprofen
complex with anti-inflammatory effects. J. Inorg. Biochem., 41,
1991; 45–51.
78. Larsen C, Jensen BH, Olesen HP. Bioavailability of ketoprofen
from orally administered ketoprofen-dextran ester prodrugs in the
pig. Acta. Pharm. Nord., 3, 1991; 71–76.
79. Giammona G, Carlisi B, Pitarresi G, Fontana G. Hydrophilic and
hydrophobic polymeric derivatives of anti-inflammatory agents
such as alclofenac, ketoprofen and ibuprofen. J. Bioact Compat.
Polym., 6, 1991; 129–141.
80. Sugimoto M, Kojima T, Asami M, Lizuka Y, Matsuda K. Inhibition
of prostaglandin production in the inflammatory tissue by
loxoprofen-Na, an anti-inflammatory prodrug. Biochem.
Pharmacol., 42, 1991; 2363-2368.
81. Zorc B, Butula I. Macromolecular prodrugs III - Esters of
fenoprofen and probenecid. Acta Pharm., 44, 1994; 103–108.
226
82. Mork N, Bundgaard H. Stereoselective enzymatic hydrolysis of
various ester prodrugs of ibuprofen and flurbiprofen in human
plasma. Pharm. Res., 9, 1992; 492–496.
83. Shanbhag VR, Crider AM, Gokhale R, Harpani A, Dick RM. Ester
and amide prodrugs of ibuprofen and naproxen: Synthesis, anti-
inflammatory activity, and gastrointestinal toxicity. J. Pharm.
Sci., 81, 1992; 149–154.
84. Otis MF, Levesque L, Marceau F, Lacroix J, Gaudreault RC.
Synthesis and pharmacological evaluation of amide derivatives of
non-steroidal anti-inflammatory drugs. Inflammopharmacology,
1, 1992; 201–212.
85. Larsen F, Jensen BH, Olesen HP, Larsen C. Multiple oral
administration of a Ketoprofen–Dextran ester prodrug in pigs:
Assessment of gastrointestinal unavailability by deconvolution.
Pharm. Res., 9, 1992; 915–919.
86. Tammara VK, Narurkar MM, Crider AM, Khan MA. Synthesis and
evaluation of morpholinoalkyl ester prodrugs of indomethacin
and naproxen. Pharm. Res., 10, 1993; 1191-1199.
87. Tammara VK, Narurkar MM, Crider AM, Khan MA.
Morpholinoalkyl ester prodrugs of diclofenac: Synthesis, invitro
and invivo evaluation. J. Pharm. Sci., 83, 1994; 644-648.
88. Roy SD, Manoukian E. Permeability of ketorolac acid and its ester
analogs (prodrug) through human cadaver skin. J. Pharm. Sci.,
83, 1994; 1548–1553.
227
89. DeCaprariis P, Palagiano F, Bonina F, Montenegro L, D'Amico M,
Rossi F. Synthesis and pharmacological evaluation of
oligoethylene ester derivatives as indomethacin oral prodrugs. J.
Pharm. Sci., 83, 1994; 1578–1581.
90. Bansal AK, Dubey R, Khar RK. Quantitation of activity of alkyl
ester prodrugs of ibuprofen. Drug Dev. Ind. Pharm., 20, 1994;
2025-2034.
91. Murtha JL, Ando HY. Synthesis of the cholesteryl ester prodrugs
cholesteryl ibuprofen and cholesteryl flufenamate and their
formulation into phospholipid micro emulsions. J. Pharm. Sci.,
83, 1994; 1222-1228.
92. Hayball PJ, Holman JW, Nation RL, Massy-Westropp RA, Hamon
DP. Marked enantioselective protein binding in humans of
ketorolac in vitro: Elucidation of enantiomer unbound fractions
following facile synthesis and direct chiral HPLC resolution of
tritium-labelled ketorolac. Chirality, 6, 1994; 642–648.
93. Tsunematsu H, Yoshida S, Horie K, Yamamoto M. Synthesis and
the stereoselective enzymatic hydrolysis of flurbiprofen-basic
amino acid ethyl esters. J. Drug. Target., 2, 1995; 517–525.
94. Bonina FP, Montenegro L, Caprariis P, Palagiano, Trapani G, Liso
G. In vitro and in vivo evaluation of polyoxyethylene indomethacin
esters as dermal prodrugs. J. Control. Rel., 34, 1995; 223–232.
95. Samara E, Anvir D, Ladkani D, Bialer M. Pharmacokinetic
analysis of diethylcarbonate prodrug of ibuprofen and naproxen.
Biopharm. Drug Dispos., 16, 1995; 201–210.
228
96. Bhosle D, Bharambe S, Gairola N, Dhaneshwar SS. Mutual
prodrug concept: Fundamentals and applications, Ind. J. Pharm.
Sci., 68, 2006; 286-294.
97. Ogiso T, Iwaki M, Tanino T, Nagai T, Ueda Y, Muraoka O, Tanabe
G. Pharmacokinetics of indomethacin ester prodrugs:
gastrointestinal and hepatic toxicity and the hydrolytic capacity of
various tissues in rats. Biol. Pharm. Bull., 19, 1996; 1178-1183.
98. Fukuhara A, Imai T, Otagiri M. Stereoselective disposition of
flurbiprofen from a mutual prodrug with a histamine H2-
antagonist to reduce gastrointestinal lesions in the rat. Chirality,
8, 1996; 494–502.
99. Aboul-Fadl T, Fouad EA. Synthesis and invitro investigation of
nalidixic acid amides of amino acid esters as prodrugs.
Pharmazie, 51, 1996; 30–33.
100. Akgun H, Tozkoparan B, Ertan M, Aksu F, Inan SY. Synthesis of
some 2-aryl propionic acid amides as prodrugs. Arzneimittel-
Forschung/Drug Res., 46, 1996; 891-894.
101. Bonina FP, Montenegro L, Caprariis P, Palagiano F, Capasso A,
Sorrentino L. Pharmacokinetic and pharmacodynamic profile of
triethylene glycol indomethacin ester as a new oral prodrug. J.
Control. Rel., 41, 1996; 187–193.
102. Tabrizi MHN, Davaran S, Entezami A. Synthesis of diclofenac
polymeric prodrugs and their hydrolysis reactivity. Iran. Polymer
J., 5, 1996; 243–249.
229
103. Bonina F, Trombetta D, Borzi A De Pasquale A, Saija A. 1-
ethylazacycloalkan-2-one indomethacin esters as new oral
prodrugs: Chemical stability, enzymatic hydrolysis, anti-
inflammatory activity and gastrointestinal toxicity. Int. J. Pharm.,
156, 1997; 245–250.
104. Palagiano F, Arenare L. Barbato F, La Rotonda MI, Quaglia F,
Bonina FP, Montenegro L, de Caprarüs P. Invitro and invivo
evaluation of terpenoid esters of indomethacin as dermal
prodrugs. Int. J. Pharm., 149, 1997; 171–182.
105. Davaran S, Entezami AA. Acrylic type polymers containing
ibuprofen and indomethacin with difunctional spacer group:
synthesis and hydrolysis. J. Control. Rel., 47, 1997; 41–49.
106. Jilani JA, Najib NM, Ghariabeh SH. Synthesis and evaluation of
some acyloxyethyl mefenamates as possible prodrugs. Acta.
Pharma. Hung., 67, 1997; 99–104.
107. Jilani JA, Pillai GK, Salem MS, Najib NM. Evaluation of
hydroxyethyl esters of mefenamic acid and diclofenac as
prodrugs. Drug Dev. Ind. Pharm., 23, 1997; 319–323.
108. Rautio J, Taipale H, Gynther J, Vepsalainen J, Nevalainen, T,
Jarvinen T. In vitro evaluation of acyloxyalkyl esters as dermal
prodrugs of ketoprofen and naproxen. J. Pharm. Sci., 87, 1998;
1622–1628.
109. Aborodo EA, Bowden K, Huntingon AP, Powell SL. Prodrugs Part
31. 2-Formylphenyl esters of indomethacin, ketoprofen and
230
ibuprofen and 6-substituted 2-formyl and 2-acylphenyl esters of
aspirin. II Farmaco, 53, 1998; 95–101.
110. Omar FA. Cyclic amide derivatives as potential prodrugs.
Synthesis and evaluation of N-hydroxymethyl phthalimide esters
of some non-steroidal anti-inflammatory carboxylic acid drugs.
Eur. J. Med. Chem., 33, 1998; 123-131.
111. Rautio J, Nevalainen T, Taipale H, Vepsalainen J, Gynhter J,
Pedersen T, Jarvinen T. Synthesis and in vitro evaluation of
aminoacyloxyalkyl esters of 2-(6-methoxy-2-naphthyl)propionic
acid as novel naproxen prodrugs for dermal drug delivery. Pharm.
Res., 16, 1999; 1172-1178.
112. Thorsteinsson T, Masson M, Loftsoson T, Haraldsson GG,
Stefansson E. Diacyl glyceryl ester prodrugs for slow release in
the skin: synthesis and in vitro degradation and absorption
studies for naproxen derivatives. Pharmazie, 54, 1999; 831-836.
113. Mahfouz NM, Omar FA, Aboul-Fadl T. Cyclic amide derivatives as
potential prodrugs II: N-hydroxy methyl succinimide/isatin esters
of some NSAIDs as prodrugs with an improved therapeutic
profile. Eur. J. Med. Chem., 34, 1999; 551-562.
114. Redden PR, Melanson RL, Douglas JA, Dick AJ. Acyloxymethyl
acidic drug derivatives: in vitro hydrolytic reactivity. Int. J.
Pharm., 180, 1999; 151–160.
115. Abo–Ghalia MH, Shalaby AM, El–Eraqi WI, Awad HM. Synthesis
and anti-phlogistic potency of some new non-proteinogenic amino
acid conjugates of „Diclofenac‟. Amino Acids, 16, 1999; 425–440.
231
116. Kourounakis AP, Galanakis D, Tsiakitzis K, Rekka EA,
Kourounakis PN. Synthesis and pharmacological evaluation of
novel derivatives of anti-inflammatory drugs with increased
antioxidant and anti-inflammatory activities. Drug Dev. Res., 47,
1999; 9–16.
117. Lastra A, Motilva C, Martin LJ, Nieto A, Barranco MD, Cabeza J,
Herrerias JM. Protective effects of melatonin on indomethacin
induced gastric injury in rats. J. Pineal Res., 26, 1999; 101-107.
118. Kourounakis PN, Tsiaitzis AP, Galanki D. Reduction of
gastrointestinal toxicity of NSAIDs via molecular modifications
leading to antioxidant anti-inflammatory drugs. Toxicology, 144,
2000; 205-210.
119. Jung YL, Lee JS, Kim YM. Synthesis and in vitro/in vivo
evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of
5-aminosalicylic acid. J. Pharm. Sci., 89, 2000; 594-602.
120. Bansal AK, Khar RK, Dubey R, Sharma AK. Activity profile of
glycolamide ester prodrugs of ibuprofen. Drug Dev. Ind. Pharm.,
27, 2001; 63-70.
121. Chandrasekar MJ, Ravichandran M, Nanjan MJ, Suresh B.
Synthesis and evaluation of a non steroidal anti-inflammatory
polymeric prodrug for sustained and site-specific delivery. Drug
Dev. Ind. Pharm., 27, 2001; 959-964.
122. Bansal AK, Khar RK, Dubey R, Sharma AK. Alkyl ester prodrugs
for improved topical delivery of ibuprofen. Ind. J. Exp. Biol., 39,
2001; 280-283.
232
123. Bonina FP, Puglia C, Barbuzzi T, De Caprariis P, Palagiano F,
Rimoli MG, Saija A. Invitro and invivo evaluation of
polyoxyethylene esters as dermal prodrugs of ketoprofen,
naproxen and diclofenac. Eur. J. Pharm. Sci., 14, 2001; 123-134.
124. Bonina F, Puglia C, Santagati NA, Saija A, Tomaino A, Tita B.
Oligoethylene ester derivatives of ketoprofen, naproxen and
diclofenac as oral prodrugs: a pharmacological evaluation.
Pharmazie, 57, 2002; 552-555.
125. Dhaneshwar SS, Ghodeswar BC, Bhojani MR. Synthesis and
biological evaluation of glucosamine conjugate prodrug of
flurbiprofen. Ind. Drugs, 40, 2003; 156-159.
126. Khan MSY, Khan RM. Synthesis and biological evaluation of
glycolamide esters as potential prodrugs of some non-steroidal
anti-inflammatory drugs. Ind. J. Chem., 41B, 2002; 2172-2175.
127. Sheha M, Khedr A, Elsherief H. Biological and metabolic study of
naproxen–propyphenazone mutual prodrug. Eur. J. Pharm. Sci.,
17, 2002; 121-130.
128. Wang LF, Chiang HN, Wu PC. Kinetics and hydrolysis mechanism
of polymeric prodrugs containing ibuprofen, ketoprofen, and
naproxen as pendent agents. J. Biomater. Sci. Polymer, 13, 2002;
287-299.
129. Sharma V, Khan MSY. Prodrugs and mutual prodrugs: Synthesis
of some new pyrazolone and oxadiazole analogues of few non
steroidal anti-inflammatory drugs. Pharmazie, 58, 2003; 99-103.
233
130. Hoogstraate J, Andersson LI, Berge OG, Jonzon B, Ojteg G. COX-
inhibiting nitric oxide donators (CINODs) - a new paradigm in the
treatment of pain and inflammation. Inflammopharmacology, 11,
2003; 423-428.
131. Whittle BJR. Mechanisms underlying intestinal injury induced by
anti-inflammatory COX inhibitors. Eur. J. Pharmacol., 500, 2004;
427-439.
132. Takeuchi K, Mizoguchi H, Araki H, Komoike Y, Suzuki K. Lack of
gastric toxicity of nitric oxide-releasing indomethacin, NCX-530,
in experimental animals. Dig. Dis. Sci., 46, 2001; 1805-1818.
133. Kaza CS, Kashfi K, Rigas B. Colon cancer prevention with
NOreleasing NSAIDs. Prost. Other Lipid Mediat., 67, 2002; 107-
120.
134. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P,
Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in
healthy human volunteers: a proof of concept endoscopic study.
Gastroenterology, 124, 2003; 600-607.
135. Yeha RK, Chena J, Williamsa JL, Balucha M, Hundleya TR,
Rosenbauma RE, Kalalaa S, Traganosb F, Benardinic F, Soldatoc
P, Kashfid K, Rigasa B. NO-donating nonsteroidal anti-
inflammatory drugs (NSAIDs) inhibit colon cancer cell growth
more potently than traditional NSAIDs: a general pharmacological
property?. Biochem. Pharmacol., 67, 2004; 2197-2205.
136. Jonzon B, Bjarnason I, Hawkey C, Jones J, Goddard A,
Fagerholm U, Karlsson P. The CINOD, AZD3582, exhibits an
234
improved gastrointestinal safety profile compared with naproxen
in healthy volunteers. Inflammopharmacology, 11, 2003; 437-
444.
137. Cena C, Lolli ML, Lazzarato L, Guaita E, Morini G, Coruzzi G,
McElroy SP, Megson IL, Fruttero R, Gasco A. Antiinflammatory,
gastrosparing, and antiplatelet properties of new NO-donor esters
of aspirin. J. Med. Chem., 46, 2003; 747-754.
138. Marshall M, Moore PK. Effect of nitric oxide releasing paracetamol
and flurbiprofen on cytokine production in human blood. Eur. J.
Pharmacol., 483, 2004; 317-322.
139. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for
cancer prevention. Trends Mol. Med., 10, 2004; 324-330.
140. Ellis JL, Augustyniak ME, Cochran ED, Earl RA, Garvey DS,
Gordon LJ, Janero DR, Khanapure SP, Letts LG, Melim TL, Murty
MG, Schwalb DJ, Shumway MJ, Selig WM, Trocha AM, Young
DV, Zemtseva IS, James E. NMI-1182, a gastro-protective cyclo-
oxygenase inhibiting nitric oxide donor. Inflammopharmacology,
12, 2004; 521-534.
141. Downing JEG, Madden JC, Ingram MJ, Rostron C. Gastric and
thymic assay of acute oral treatment of rats with nitric oxide
esters of ibuprofen or indomethacin. Biochem. Biophys. Res.
Commun., 334, 2005; 646-653.
142. Velazquez C, PraveenRao PN, Knaus EE. Novel non steroidal anti
inflammatory drugs possessing a nitric oxide donor diazen- 1-
ium-1,2-diolate moiety: Design, synthesis, biological evaluation
235
and nitric oxide release studies. J. Med. Chem., 48, 2005; 4061-
4067.
143. Ranani RR, Michael E. Synthesis and anti-inflammatory activity
of a series of N-substituted naproxen glycolamides: Nitric
oxidedonor naproxen prodrugs. Bioorg. Med. Chem., 14, 2006;
2589-2599.
144. Khan MSY, Akhter M. Synthesis, pharmacological activity and
hydrolytic behavior of glyceride prodrugs of ibuprofen. Eur. J.
Med. Chem., 40, 2005; 371-376.
145. Zhao X, Tao X, Wei D, Song Q. Pharmacological activity and
hydrolysis behavior of novel ibuprofen glucopyranoside
conjugates. Eur. J. Med. Chem., 41, 2006; 1352-1358.
146. Shiang PY, Chun LS, Jer HS, Ming WY, Jer LY, Fang WL, Shing
CJ. Chondroitin sulfate-based anti-inflammatory macromolecular
prodrugs. Eur. J. Pharm. Sci., 29, 2006; 60-69.
147. Halen PK, Chagti, KK, Giridhar R, Yadav MR. Substituted
aminoalcohol ester analogs of indomethacin with reduced toxic
effects. Med. Chem. Res., 16, 2007; 101-111.
148. Carlos A, Velazquez PN, Rao P, Citro ML, Keefer L, Knaus EE. O2-
Acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-
NSAIDs): Synthesis, nitric oxide release, and biological evaluation
studies. Bioorg. Med. Chem., 15, 2007; 4767-4774.
149. Fiorucci S, Antonelli E, Distrutti E, Rizzo G, Mencarelli A, Orlandi
S, Zanardo R, Renga B, Di Sante M, Morelli A, Cirino G, Wallace
JL. Inhibition of hydrogen sulfide generation contributes to
236
gastric injury caused by anti inflammatory non steroidal drugs.
Gastroenterology, 129, 2005; 1210-1224.
150. Wallace J, Cirino G, Santagada V, Caliendo G. United States
Patent, Hydrogen sulphide derivatives of non-steroidal anti-
inflammatory drugs. US 2008/0004245 A1, Jan 3, 2008.
151. Mishra A, Veerasamy R, Jain KP, Dixit VK, Agrawal RK.
Synthesis, characterization and pharmacological evaluation of
amide prodrugs of ketorolac. Eur. J. Med. Chem., 43, 2008;
2464-2472.
152. Vyas S, Trivedi P, Chaturvedi SC. Ketorolac-dextran conjugates:
Synthesis, invitro and invivo evaluation, Acta Pharm., 57, 2007;
441-450.
153. Mohan R, Ramaa CS. Ester prodrugs of flurbiprofen: Synthesis,
plasma hydrolysis and gastrointestinal toxicity. Ind. J. Chem.,
46-B, 2007; 1164-1168.
154. Lohade AA, Jain P, Iyer KR. Parallel combinatorial synthesis and
invitro evaluation of ester and amide prodrugs of flurbiprofen,
ibuprofen and ketoprofen. Ind. J. Pharm. Edu. Res., 43, 2009;
140-149.
155. Sharma R, Sharma CL. Macromolecular drugs: Novel strategy in
target specific drug delivery. J Clin. Diag. Res., 2, 2008; 1020-
1023.
156. Onishi H, Machida Y. Invitro and invivo evaluation of micro
particulate drug delivery systems composed of macromolecular
prodrugs. Molecules, 13, 2008; 2136-2155.
237
157. Penugonda S, Kumar A, Agarwal HK, Parang K, Mehvar R.
Synthesis and invitro characterization of novel dextran-methyl
prednisolone conjugates with peptide linkers: Effects of linker
length on hydrolytic and enzymatic release of methyl
prednisolone and its peptidyl intermediates. J. Pharm. Sci., 97,
2008; 2649-2664.
158. Varshosaz J, Emami J, Fassihi A, Tavakoli N, Minaiyan M,
Ahmadi F, Dorkoosh F. Synthesis and evaluation of dextran–
budesonide conjugates as colon specific prodrugs for treatment of
ulcerative colitis. Int. J. Pharm., 365, 2009; 69-76.
159. Manon B, Sharma PD. Design, synthesis and evaluation of
diclofenac-antioxident mutual prodrugs as safer NSAIDs. Ind. J.
Chem., 48(B), 2009; 1279-1287.
160. Pugazhendhy S, Shrivastava PK, Sinha SK, Shrivastava SK.
Lamotrigine–dextran conjugates: Synthesis, characterization and
biological evaluation. Med Chem. Res., Online First, May, 2010.
DOI: 10.1007/s00044-010-9355-9
161. Shrivastava PK, Shrivastava SK. Dextran carrier macromolecule
for colon specific delivery of celecoxib. Curr. Drug Del., 7, 2010;
144-151.
162. Aceclofenac. Monographs: Medicinal and Pharmaceutical
Substances. British Pharmacopoeia Volume I, 2009; 1-5.
163. Barar FSK. Essentials of Pharmacotherapeutics, S. Chand, New
Delhi, 2000; 1-295.
238
164. Shaik KA, Devkhile AB. Simultaneous determination of
aceclofenac, paracetamol and chlorzoxazone by RP-HPLC in
pharmaceutical dosage form. J. Chromato. Sci., 46, 2008; 649-
652.
165. Soni T, Chotai N. Assessment of dissolution profile of marketed
aceclofenac formulations. J. Young Pharmacists, 2, 2010; 21-26.
166. Malakar S, Rao SB, AshokKumar P, Kulkarni SV. Formulation
and evaluation of fast dispersible aceclofenac tablets: effect of
functionality of super disintegrants. J. Global Pharma. Tech., 2,
2010; 90-96.
167. Azhlwar S, Ravi TK. Simultaneous densitometric analysis of
drotaverine and aceclofenac by HPTLC method. Der Pharmacia
Lettre, 2, 2010; 328-332.
168. Cahill WJ, Hill RD, Jessop J, Kendall PH. Trial of mefenamic acid.
Rheumat., 8, 1965; 26-29.
169. The Merck Index - An Encyclopedia of Chemicals, Drugs and
Biologicals, Merck, USA, 1989; 1-3757.
170. Martindale - The Complete Drug Reference, Pharmaceutical
Press, London, 2002; 1-732.
171. Bennett PN, Brown MJ. Clinical Pharmacology, Churchill
Livingstone, Edinburgh, 2003; 1-584.
172. Rang HP, Dele MM, Ritter JM. Pharmacology, Churchill
Livingstone, Edinburgh, 1996; 1-349.
173. Raza A. Spectrophotometric determination of mefenamic acid in
pharmaceutical preparations. J. Anal. Chem., 63, 2008; 244-247.
239
174. Jawla S, Jain S. atomic absorption spectrometric method for
estimation of diclofenac sodium and mefenamic acid in
pharmaceutical formulations. Int. J. Pharm. Sci. Drug Res., 2,
2010; 45-47.
175. Alarfaj NA, Altamimi SA, Almarshady LZ. Spectrophotometric
determination of mefenamic acid in pharmaceutical preparations.
Asian J. Chem., 21, 2009; 217-226.
176. Kaehler ST, Phleps W, Hesse E. Dexibuprofen: Pharmacology,
therapeutic uses and safety. Inflammopharmacology, 11, 2003;
371-383.
177. Bonabello A, Galmozzi MR, Canaparo R, Isaia GC, Serpe L,
Muntoni E, Zara GP. Dexibuprofen (S(+)-isomer ibuprofen)
reduces gastric damage and improves analgesic and anti
inflammatory effects in rodents. Anesth. Analg., 97, 2003; 402-
408.
178. Cheng H, Rogers JD, Demetriades JL, Holland SD, Seivold JR,
Depuy E. Pharmacokinetics and bioinversion of ibuprofen
enantiomers in humans. Pharm. Res., 11, 1994; 824-830.
179. Geisslinger G, Schuster O, Stock KP. Pharmacokinetics of S(_)-
and R(_)-ibuprofen in volunteers and first clinical experience of
S(_)-ibuprofen in rheumatoid arthritis. Eur. J. Pharmacol., 38,
1990; 493-497.
180. Muralidharan S, Meyyanathan SN, Muruganantham N, Rajan S,
Krishnaraj K, Suresh B. Validated HPTLC method of analysis of
240
dexibuprofen in its formulation. J. Planar Chrom., 22, 2009; 207-
210.
181. Chitlange SS, Soni R, Wankhede SB, Kulkarni AA.
Spectrophotometric methods for simultaneous estimation of
dexibuprofen and paracetamol. Asian J. Res. Chem., 2, 2009; 30-
33.
182. Yi HG, Chi MH, Kim Y, Woo JS, Park ES. Formulation of a
extended release tablet containing dexibuprofen. Arch. Pharm.
Res., 31, 2008; 1637-1643.
183. Ravichandran V, Mishra A, Agrawal RK, Dixit VK. Synthesis,
characterization and pharmacological evaluation of amide
prodrugs of flubiprofen. J. Braz. Chem. Soc., 19, 2008; 89-100.
184. Streitwieser Jr. A, Heathcock GH. Introduction to organic
chemistry. Macmillan Publishing Company, New York, 1989; 1-
947.
185. Norman ROC, Coxon JM. Principles of organic synthesis.
Chapman and Hall, London, 1993; 1-590.
186. Martin A, Swarbrick J, Cammarata A. Physical pharmacy. Lea
and Febiger, Philadelphia, 1983; 408-409.
187. The Merck Index - An Encyclopedia of chemicals, drugs and
biologicals. Merck Research Laboratories Division, Merck and Co.
Inc., White House Station, New Jersey, 1996; 1-908.
188. Indian Pharmacopoeia, Vol. I, Controller of Publication, New
Delhi, Government of India, Ministry of Health and Family
Welfare, 1996.
241
189. Sherma J, Fried B, Dekker M. Handbook of thin-layer
chromatography. New York, 1996; 1-1104.
190. Willard HH, Merritt LL, Dean JA, Settle FA. Instrumental methods
of analysis. CBS publishers, 1986; 1-895.
191. Qiu Y, Chen Y, Liu L, Geoff G, Zhang Z. Developing solid oral
dosage forms: Pharmaceutical theory and practice. Academic
Press, USA, 2009; 1-943.
192. Silverstein RM, Webster FX. Spectrophotometric identification of
organic compounds. John Wiley and Sons Inc., New York, 1998;
1-502.
193. Kemp W, Organic Spectroscopy. MacMillan Press Ltd., London,
1991; 1-416.
194. Sethi PD. Quantitative analysis of drugs in pharmaceutical
formulations. CBS Publishers, Delhi, 2008; 1-643.
195. Leo A, Hansch C, Elkins D. Partition coefficients and their uses.
Chem. Rev., 71, 1971; 525–616.
196. Eadsforth CV, Moder P. Assessment of reverse-phase
chromatographic methods for determining partition coefficients.
Chemosphere, 12, 1983; 1459-1475.
197. Ewart A. Remington‟s Pharmaceutical Sciences. Mac Publishing
Company, Easton, 1980; 873-74.
198. Goldstien A. The interactions of drugs and plasma proteins.
Pharmacol. Rev., 1, 1949; 102-165.
199. Stephen HC. Drug disposition and pharmacokinetics. Blackwell
Scientific Pub1icaton, Oxford, 1977; 1-275.
242
200. March J. Advanced organic chemistry: Reactions mechanisms
structure. John Wiley and Sons Publisher, USA,1992; 1-1512.
201. The United state Pharmacopoeia, 22 revision, United States
Pharmacopoeial Convention Inc., Rockvile, MD, 1990; 1026-1027.
202. Dev S, Deepali VM, Kadam SS, Dhaneshwar SR. Synthesis and
pharmacological evaluation of cyclodextrin conjugate prodrug of
mefenamic acid. Ind. J. Pharm. Sci., 69, 2007; 69-72.
203. Zhao X, Tao X, Wei D, Song Q. Pharmacological activity and
hydrolysis behavior of novel ibuprofen glucopyranoside
conjugates. Eur. J. Med. Chem., 41, 2006; 1352-1358.
204. Metwally KA, Yaseen SH, Lashine EM, El-Fayomi HM, El-Sadek
ME. Non-carboxylic analogues of arylpropionic acids: Synthesis,
anti-inflammatory activity and ulcerogenic potential. Eur. J. Med.
Chem., 42, 2007; 152-160.
205. Peppas NA, Sahlin JJ. A simple equation for the description of
solute release, III. Coupling of diffusion and relaxation. Int. J.
Pharm., 57, 1989; 169-172.
206. Sujja-areevath J, Munday DL, Cox PJ, Khan KA. Relationship
between swelling, erosion and drug release from hydrophilic
natural gum mini-matrix formulations. Eur J Pharm Sci., 6,
1998; 207–217.
207. Bamba M, Puisieusx F, Marty JP, Carstensen JT. Release
mechanisms in gel forming sustained release preparations. Int. J.
Pharm., 2, 1979; 307-315.
243
208. Chien YW. Fundamentals of controlled release drug
administration. In: Novel Drug Delivery System (Swarbrick J,
Ed.). New York, Marcel Dekker Inc., 1982, 465–574.
209. Bolton S. Pharmaceutical statistics. New York, Marcel Dekker
Inc., New York, 1990; 234-236.
210. Gohel MC, Panchal MK. Formulation optimization of diltiazem
HCl matrix tablets containing modified guar gum using a central
composite design. Pharm. Pharmacol. Commun., 5, 1999; 331-
338.
211. Higuchi T. Mechanism of sustained action medication: theoretical
analysis of rate of release of solid drugs dispersed in solid
matrices. J. Pharm. Sci., 52, 1963; 1145-1149.
212. Wagner JG. Sustained action oral medication II. The kinetics of
release of drugs to fluid in vitro. Drug Std., 27, 1959; 178-186.
213. Fessi H, Marty JP, Puisieux F, Carstensen JT. Square root of time
dependence of matrix formulation with low drug content. J.
Pharm. Sci., 71, 1982; 749-752.
214. Gohel MC, Amin AF. Formulation optimization of controlled
release diclofenac sodium microspheres using factorial design. J.
Control. Rel., 51, 1998; 115-122.
215. Wiegand RG, Taylor JD. Kinetics of plasma drug levels after
sustained release dosage. Biochem. Pharmacol., 3, 1960; 256-
263.
216. Shrivastava SK, Jain DK, Trivedi P. Dextrans–potential polymeric
drug carriers for flurbiprofen. Pharmazie, 58, 2003; 389–391.
244
217. Spector WG, Willoughby DA. Salicylate and increased vascular
permeability. Nature, 196, 1962; 1104.
218. Brown JH, Mackey HK. Inhibition of heat-induced denaturation of
serum proteins by mixtures of non-steroidal anti-inflammatory
agents and amino acids. Proc. Soc. Exp. Biol. Med., 128, 1968;
225-228.
219. Hamor GH. Principles of medicinal chemistry (Foye WO. Eds). Lea
and Febiger, Philadephia, l981; 1-561.
220. Winter CA, Risely EA, Nuss GW. Carregeenan induced oedema in
hind paw of the rat as assay for anti-inflammatory drugs. Proc.
Soc. Exp. Biol. Med., 111, 1962; 544-547.
221. Kellett DN. On the anti-inflammatory activity of protamine
sulphate and of hexadimethrine bromide, inhibitors of plasma
kinin formation. Br. J. Pharmacol. Chemother., 24, 1965; 705-
713.
222. Fukuhara M, Tsurufuji S. The effect of locally injected anti-
inflammatory drugs on the carrageenan granuloma in rats.
Biochem. Pharma., 18, 1969; 475-484.
223. Swingle KF, Bell RL, Moore GGI, Anti inflammatory activity of
antioxidants. In: Anti-Inflammatory and Anti-Rheumatic Drugs.
Vol. III: Anti-Rheumatic Drugs, Experimental Agents and Clinical
Aspects of Drug Use (Rainsford KD Ed). CRC Press, Boca Raton,
1985; 105-126.
224. Neha G, Deepika N, Suneela SD, Dhaneshwar SR, Chaturvedi SC.
Synthesis, hydrolysis, kinetics and pharmacodynamic profiles of
245
novel prodrugs of flubiprofen. Ind. J. Pharm. Sci., 67, 2005; 369-
373.
225. Eddy NB, Leimbach D. Synthetic analgesics. II. dithienylbutenyl
and dithienylbutylamines. J. Pharmacol. Exp. Ther., 107, 1953;
385-393.
226. Kazunaga F, Osamu K, Morihide H, Noriyuki M, Seiichi O,
Yoshikazu H. A method for evaluating analgesic agents in rats. J.
Pharmacol. Methods, 4, 1980; 251-259.
227. Bianchi C. Franceschini J. Experimental observations on
Haffner's method for testing analgesic drugs.Br. J. Pharmacol.
Chemother., 9, 1954; 280–284.
228. D‟Amour FE, Smith DL. A method for determining loss of pain
sensation. J. Pharmacol. Exp. Ther., 72, 1941; 74-79.
229. Alagarsamy V, Shankar D, Solomon VR. Synthesis of some novel
2-mercapto-3-(substituted amino)-5, 6, 7, 8-tetra hydro-3H-benzo
[4, 5] thieno [2, 3d] pyrimidin-4-ones as analgesic and anti-
inflammatory agents. Arkivoc., 16, 2006; 149-159.
230. Coili V, Putzolu S, Rossi V, Barcellona PS, Corradino C. The role
of direct tissue contact in the production of gastrointestinal
ulcers by anti-inflammatory drugs in rats. Toxicol. Appl.
Pharmacol., 50, 1979; 283-289.
231. Brodie DA, Cook PG, Bauer BJ, Dagle GE. Indomethacin-induced
intestinal lesions in the rat. Toxicol. Applied Pharmacol., 17,
1970; 615-624.
246
232. Hersey SJ, Sachs G. Gastric acid secretion. Physiol. Rev., 75,
1995; 155-189.
233. El-Zimaity HMT, Verghese VJ, Singh JR, Graham DY. The gastric
cardia in gastro-oesophageal disease. J. Clin. Pathol., 53, 2000;
619-625.
234. Shah AH, Khan ZA. Gastroprotective effects of pretreatment with
Zizyphus sativa fruits against toxic damage in rats. Fitoterapia, 3,
1997; 226–234.
235. Yagmurca M, Ucar M, Fadillioglu E, Erdogan H, Ozturk F. The
effects of nitric oxide on rat stomach injury induced by
acetylsalicylic acid. Turk. J. Med. Sci., 39, 2009; 13-19.